Immunoprecise highlights combo neutralization of antibodies

By The Science Advisory Board staff writers

July 31, 2020 -- Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit enhanced neutralization upon combinatorial testing.

Previously, the company demonstrated potent in vitro neutralizing activity of functional antibodies discovered using its DeepDisplay phage technology, B Cell Select, and single-step hybridoma platforms. Now, the company has confirmed that six antibodies covering three epitopes analyzed for enhanced function in combination studies resulted in near complete SARS-CoV-2 pseudovirus infection.

Efforts continue to further analyze multiple additional subsets of antibodies including neutralizing antibodies that bind to the S1 and S2 subunit domains of the SARS-CoV-2 spike protein. The company has begun steps for expression of the lead antibodies for preclinical and clinical manufacturing.

ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...
ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...

Copyright © 2020

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter